New Approaches to Brain Tumor Therapy

Acronym

Definition

NABTT

References in periodicals archive	?		Acronyms browser	?		Full browser	?
The first IL13-PE38 clinical study is being conducted through the NCI Clinical Trial Evaluation Program (CTEP)-funded New Approaches to Brain Tumor Therapy (NABTT) Consortium. EOPHARM BEGINS NEW GLOBAL TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA by Worldwide Biotech The NABTT-0306 study, sponsored by the National Cancer Institute and run by the New Approaches to Brain Tumor Therapy (NABTT) Adult Brain Tumor Consortium, randomized 94 patients with newly diagnosed GBM to two different doses of cilengitide (500 or 2,000 mg) in combination with chemoradiotherapy to estimate overall survival as the primary endpoint. Merck KGaA: Study Shows Cilengitide Increased Overall Survival in ... by Business Wire Erimos recently commenced a Phase I study in partnership with the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma. Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and ... by Business Wire	NEVC NEVCA NEVCC NEVCO NEVD NEVDGP NEVDIS NEVE NEVES NEVFC NEVG NEVI NEVIS NEVN NEVO NEVOBO NEVOG NEVP NEVR NEVS NEVSF NEVT NEVTI NEVWG NEW New Approaches to Brain Tumor Therapy NEW ENG NEW MOONS NEW TIES NEW2AN NEWA NEWAC NEWAG NEWAN NEWAY NEWB NEWBO NEWBY NEWC NEWCA NEWCAP NEWCAS NEWCIS NEWCOM NEWD NEWDC NEWEA NEWEDC NEWEST NEWEXT NEWF	New and Used New and useful invention New Andalucia New Andalucia New Anglo-Saxon Chronicle New Animal Drug Application New Animal Drug Evaluation New Animaniacs Cultural Reference Guide New Annualized Premium New Anointing World Outreach New Antilles Movement New Anzat Order New Apostles Church International New Apostolic Church New Apostolic Reformation New Application Development New Applications License Charge New Appointments Scheme for Clinical Academics New Apprentice Centre New Apprenticeship Authorisation Number New Approach Anti-Drug Program New Approach Notified and Designated Organisations New Approach to Treating Rape Victims New Approach to Treating Rape Victims New Approach to Treating Rape Victims New Approach to Treating Rape Victims New Approaches to Brain Tumor Therapy New Approaches to Lifelong Learning New Approaches to Neuroblastoma Therapy New Arab Woman Forum New Arcade Operation Machine Idea New Archangel New Architectures for Optical Processing in Industrial Applications New Ark United Church of Christ New Armenian Resistance New Armenian Resistance Organization New Army Authorization Documents System New Around Here New Around Here Are You New Arrangements to Borrow New Arrangements to Borrow New Arrangements to Borrow New Arrangements to Borrow New Arrival New Arrival Assessment New Art Dealers Alliance New Artists to Radio New Arundel Football Association New Ash Green Village Association New Asia Professional Timer New Asian-African Strategic Partnership New Aspiration Party New Associate Orientation

References in periodicals archive

Acronyms browser

Full browser

The first IL13-PE38 clinical study is being conducted through the NCI Clinical Trial Evaluation Program (CTEP)-funded New Approaches to Brain Tumor Therapy (NABTT) Consortium.

EOPHARM BEGINS NEW GLOBAL TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA by Worldwide Biotech

The NABTT-0306 study, sponsored by the National Cancer Institute and run by the New Approaches to Brain Tumor Therapy (NABTT) Adult Brain Tumor Consortium, randomized 94 patients with newly diagnosed GBM to two different doses of cilengitide (500 or 2,000 mg) in combination with chemoradiotherapy to estimate overall survival as the primary endpoint.

Merck KGaA: Study Shows Cilengitide Increased Overall Survival in ... by Business Wire

Erimos recently commenced a Phase I study in partnership with the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma.

Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and ... by Business Wire